Skip to main content
SpringerLink
Log in

Saruplase Is a Safe and Effective Thrombolytic Agent; Observations in 1698 Patients: Results of the PASS Study

  • Published:
Journal of Thrombosis and Thrombolysis Aims and scope Submit manuscript

Abstract

Saruplase (unglycosylated human-type high molecular weight single-chain urokinase-type plasminogen activator) was given to 1698 patients in the open-label Practical Applicability of Saruplase Study (PASS), which assessed the safety and efficacy of saruplase in the treatment of acute myocardial infarction. Thirty-seven hospitals in Europe participated in the study. All patients received 20 mg saruplase as a bolus followed by an infusion of 60 mg saruplase over 1 hour. Prior to the infusion of saruplase, 62% of the patients received a bolus of 5000 U of heparin, and after saruplase a 24-hour intravenous infusion of heparin was given to 95% of patients. The mean age of the patients was 59 years and 80.1% were male. The median delay from the onset of chest pain to the start of saruplase infusion was 145 minutes. Acute angiography was performed in 8 of the participating 37 centers in 350 patients (20.6%), on average 85 minutes (median) after the start of the saruplase infusion. TIMI 3 flow was obtained in 186 patients (53.1%) and TIMI 2 flow in 61 patients (17.4%). Patency rates were similar for patients with anterior and inferior infarction. ECG signs suggestive of reperfusion were seen in 63% of the patients. In-hospital mortality was low (92 patients; 5.4%), and nonfatal recurrent myocardial infarction was seen in 60 patients (3.5%). Severe bleeding complications occurred in 92 patients (5.4%), 21 of whom (1.2%) needed a blood transfusion. An intracerebral hemorrhage was observed in eight patients (0.5%), and seven patients (0.4%) suffered from a thromboembolic stroke. At discharge 85.9% of the patients were in NYHA functional class I. One-year mortality was low (142 patients; 8.4%). Mortality was high in patients with TIMI 0 or 1 flow at the acute angiography who did not undergo rescue PTCA (9/39; 23.1%), lower in patients with TIMI 0 or 1 flow followed by successful rescue PTCA (7/64; 10.9%), and low in patients with TIMI 2 flow (1/61; 1.6%) or with TIMI 3 flow (2/186; 1.1%). Patency rates and (bleeding) complications did not differ between patients with a body weight greater than or less than 70 kilograms. No antibodies against saruplase were detected in samples from 455 patients. In conclusion, it can be stated that saruplase, given in combination with aspirin and intravenous heparin, can be given safely and effectively to patients with acute myocardial infarction.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Simoons ML, Serruys PW, vd Brand M, et al. Early thrombolysis in acute myocardial infarction: Limitation of infarct size and improved survival. J Am Coll Cardiol 1986;7:717–728.

    PubMed  Google Scholar 

  2. Gruppo Italiano per lo Studio della Streptochinasi nell' Infarto miocardico (GISSI). Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet 1986;1:397–402.

    Google Scholar 

  3. ISIS-2 (second International Study of Infarct Survival) collaborative group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected myocardial infarction. Lancet 1988;2:349–360.

    Google Scholar 

  4. AIMS trial study group. Effect of intravenous APSAC on mortality after acute myocardial infarction: Preliminary report of a placebo-controlled clinical trial. Lancet 1988;1: 842–847.

    Google Scholar 

  5. Van de Werf F, Arnold AER. Intravenous tissue type plasminogen activator and size of infarct, left ventricular function, and survival in acute myocardial infarction. Br Med J 1988;297:1374–1379.

    Google Scholar 

  6. TheGUSTOinvestigators.Aninternational randomized trial comparing four thrombolytic regimens consisting of tissue plasminogen activator, streptokinase, or both for acute myocardial infarction. N Engl J Med 1993;329:673–682.

  7. Holmes WE, Pennica D, Blaber M, et al. Cloning and expression of the gene for pro-urokinase in Escherichia coli. Bio/Technology 1985;3:923–929.

    Article  Google Scholar 

  8. PRIMI trial study group. Randomized double-blind trial of recombinant prouro-kinase against streptokinase in acute myocardial infarction. Lancet 1989;1:863–868.

    Google Scholar 

  9. Michels R, Hoffman J, Windeler J, Barth H, Hopkins G. A double-blind multicenter comparison of the efficacy and safety of saruplase and urokinase in the treatment of acute myocardial infarction: Report of the SUTAMI study group. J Thromb Thrombolys 1995;2:117–124.

    Google Scholar 

  10. Bär FW, Meyer J, Vermeer F, et al. Comparison of saruplase and alteplase in acute myocardial infarction. Am J Cardiol 1997;79:727–732.

    PubMed  Google Scholar 

  11. Bär FW, Vermeer F, Michels R, et al. Saruplase in myocardial infarction. J Thromb Thrombolys 1995;2:195–204.

    Google Scholar 

  12. Vermeer F, Hopkins GR, Windeler J, et al. Efficacy and safety data of 4317 patients with acute myocardial infarction treated within six hours after onset with saruplase. Circulation 1996;94:1–745.

    PubMed  Google Scholar 

  13. Tebbe U, Windeler J, Bösl I, et al. Thrombolysis with recombinant unglycosylated single-chain urokinase-type plasminogen activator (saruplase) in acute myocardial infarction: Influence of heparin on early patency rate (LIMITS study). J Am Coll Cardiol 1995;26:365–373.

    PubMed  Google Scholar 

  14. Vermeer F, Simoons ML, Bär FW, et al. Which patients benefit most from early thrombolytic therapy with intracoronary streptokinase. Circulation 1986;74:1379–1389.

    PubMed  Google Scholar 

  15. Doevendans P, Gorgels A, van der Zee R, et al. Electrocardiographic diagnosis of reperfusion during thrombolytic therapy in acute myocardial infarction. Am J Cardiol 1995; 75:1206–1210.

    Article  PubMed  Google Scholar 

  16. Gorgels APM, Widdershoven JWMG, De Vreede-Swagemakers JJM, et al. Has the long term prognosis of acute myocardial infarction improved with new treatments? Eur Heart J 1995;16(Suppl. E):54–56.

    Google Scholar 

  17. Fibrinolytic Therapy Trialists' Collaborative group. Indications for thrombolytic therapy in suspected acute myocardial infarction: Collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet 1994;311–322.

  18. De Jaegere PP, Arnold AA, Balk AH, Simoons ML. Intracranial hemorrhage in association with thrombolytic therapy: Incidence and clinical predictive factors. J Am Coll Cardiol 1992;2:289–94.

    Google Scholar 

  19. Moulin T, Crépin-Leblond T, Chopard JL, Bogousslavsky J. Hemorrhagic infarcts. Eur Neurol 1994;34:64–77.

    PubMed  Google Scholar 

  20. Karagounis LA, Sorensen SG, Menlove RL, Moreno F, Anderson L. Does thrombolysis in myocardial infarction (TIMI) perfusion grade 2 represent a mostly patent artery or a mostly occluded artery? Enzymatic and electrocardiographic evidence from the TEAM-2 study. J Am Coll Cardiol 1992;19:1–10.

    PubMed  Google Scholar 

  21. Lincoff AM, Topol EJ. Illusion of reperfusion. Does anyone achieve optimal reperfusion during acute myocardial infarction? Circulation 1993;87:1792–805.

    Google Scholar 

  22. Anderson JL, Karagounis LA, Becker LC, Sorensen SG, Menlove RL. TIMI perfusion grade 3 but not grade 2 results in improved outcome after thrombolysis for myocardial infarction. Ventriculographic, enzymatic and electrocardiographic evidence from TEAM-3 study. Circulation 1993;87: 1829–1839.

    PubMed  Google Scholar 

  23. Vogt A, von Essen R, Tebbe U, Feuerer W, Appel KF, Neuhaus KL. Impact of early reperfusion status of the infarct related artery after thrombolysis for acute myocardial infarction: Retrospective analysis of four German multicentre studies. J Am Coll Cardiol 1993;21:1391–1395.

    PubMed  Google Scholar 

  24. Diefenbach C, Erbel R, Pop T, et al. Recombinant singlechain urokinase-type plasminogen activator during acute myocardial infarction. Am J Cardiol 1988;61:966–970.

    PubMed  Google Scholar 

  25. Bär FW, Frederiks J, de Swart H, et al. Rescue PTCA following failed thrombolysis and primary PTCA. A retrospective study of angiographic and clincal outcome. J Thrombo Thrombolys 1997;4:281–288.

    Article  Google Scholar 

  26. Behar S, Gottlieb S, Hod H, et al. Influence of gender in the therapeutic management of patients with acute myocardial infarction in Israel. Am J Cardiol 1994;73:438–443.

    Article  PubMed  Google Scholar 

  27. Jenkins JS, Flaker GC, Nolte B, et al. Causes of higher mortality in women than in men after acute myocardial infarction. Am J Cardiol 1994;73:319–322.

    Article  PubMed  Google Scholar 

  28. Lincoff AM, Califf RM, Ellis SG, et al. Thrombolytic therapy for women with myocardial infarction: Is there a gender gap? J Am Coll Cardiol 1993;22:1780–1787.

    PubMed  Google Scholar 

  29. Karlson B, Herlitz J, Hartford M. Prognosis in myocardial infarction in relation to gender. Am Heart J 1994;128: 477–483.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University of Maastricht, Maastricht, The Netherlands

    F. Vermeer & F. Bär

  2. Grünenthal GmbH, Aachen, Germany

    I. Bösl & H. Barth

  3. Johannes Gutenberg University, Mainz, Germany

    J. Meyer

  4. University Hospital Trousseau, Tours, France

    B. Charbonnier

  5. University of Heidelberg, Heidelberg, Germany

    J. Windeler

Authors
  1. F. Vermeer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. I. Bösl
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J. Meyer
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. F. Bär
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. B. Charbonnier
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. J. Windeler
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. H. Barth
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Vermeer, F., Bösl, I., Meyer, J. et al. Saruplase Is a Safe and Effective Thrombolytic Agent; Observations in 1698 Patients: Results of the PASS Study. J Thromb Thrombolysis 8, 143–150 (1999). https://doi.org/10.1023/A:1008967219698

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1008967219698

Search

Navigation